Symposia: Myeloproliferative Syndromes: Clinical and Epidemiological
Program: Oral and Poster Abstracts
Type: Oral
Hematology Disease Topics & Pathways:
Research, clinical trials, adult, MPN, Clinical Research, Combination therapy, Chronic Myeloid Malignancies, drug development, Diseases, Therapies, Myeloid Malignancies, Study Population, Human
Type: Oral
Hematology Disease Topics & Pathways:
Research, clinical trials, adult, MPN, Clinical Research, Combination therapy, Chronic Myeloid Malignancies, drug development, Diseases, Therapies, Myeloid Malignancies, Study Population, Human
Sunday, December 10, 2023: 4:30 PM-6:00 PM
Pacific Ballroom Salons 21-22
(Marriott Marquis San Diego Marina)
Moderators:
Firas El Chaer, MD, University of Virginia Comprehensive Cancer Center
and
Gabriela S. Hobbs, MD, Massachusetts General Hospital
Disclosures:
El Chaer: Bristol Myers Squib: Research Funding; Amgen: Consultancy, Research Funding; Celgene: Research Funding; Fibrogen: Research Funding; Sumitomo Pharma Oncology: Consultancy, Research Funding; Sanofi: Research Funding; PharmaEssentia: Research Funding; BioSight: Research Funding; MEI Pharma: Research Funding; Novartis: Research Funding; Arog Pharmaceuticals: Research Funding; Association of Community Cancer Centers: Consultancy; DAVA Oncology: Other: Travel grant; CTI Biopharma: Consultancy; AbbVie: Consultancy; MorphoSys: Consultancy. Hobbs: BMS: Membership on an entity's Board of Directors or advisory committees; Abbvie: Membership on an entity's Board of Directors or advisory committees; Pharmaxis: Membership on an entity's Board of Directors or advisory committees; Pfizer: Membership on an entity's Board of Directors or advisory committees; Regeneron: Current holder of stock options in a privately-held company; Morphosys: Membership on an entity's Board of Directors or advisory committees, Research Funding; Protagonist: Membership on an entity's Board of Directors or advisory committees; Keros: Membership on an entity's Board of Directors or advisory committees; Incyte: Research Funding; Novartis: Membership on an entity's Board of Directors or advisory committees.
As the therapeutic horizon broadens for myelofibrosis, this session focuses on the key clinical trials and emerging agents that are changing the landscape of this disease. Both early-phase and long-awaited later-phase trial data will be presented, as well as pivotal new data on disease transformation.
4:30 PM
4:45 PM
5:00 PM
5:15 PM
5:30 PM
5:45 PM
See more of: Oral and Poster Abstracts
*signifies non-member of ASH